SECURE-CODE-WARRIOR
23.7.2024 14:01:30 CEST | Business Wire | Press release
Secure Code Warrior, the global, developer-driven security leader, today announced the availability of SCW Trust Agent – an industry-first solution that assesses the specific security competencies of developers for every code commit. This innovative offering enables CISOs and application security (AppSec) teams to embrace a Secure-by-Design approach with deeper visibility into their organizations’ software development security posture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723230392/en/
SCW Trust Agent provides visibility and control to scale developer driven security (Photo: Business Wire)
The launch of SCW Trust Agent follows the company’s rollout of SCW Trust Score, the first industry benchmark that quantifies the security posture of organizations’ developer teams. Both innovations apply over 20 million learning data points collected from 250,000 developers around the world. These deliver quantitative mechanisms that, when paired with Secure Code Warrior’s agile learning platform, become an integral part of an organization’s secure software development lifecycle.
“At Secure Code Warrior, we are unlocking new value for CISOs by giving them an easy-to-deploy solution to measure the health of code commits and visibility into the hundreds of source code repositories in their organization,” said Pieter Danhieux, Co-founder and CEO, Secure Code Warrior. “Our innovations are putting organizations in a better position to bridge the visibility gap between a developer's skill sets and quality of code produced without sacrificing development velocity.”
SCW Trust Agent works seamlessly with any Git-based code repository including GitHub, GitLab, Atlassian Bitbucket and more. With every commit, it looks to see if the developer making it has the prescribed secure code skillset in the commit’s programming language. It uses this information to give a rating on the health of that commit and aggregates these ratings across all of your repositories.
SCW Trust Agent delivers greater control and flexibility for developer gatekeeping. It allows administrators to set up policies and criteria, ensuring developers meet a baseline set of standards and expectations before developing code. For any gaps in developer skills, they can reference the SCW agile learning platform to upskill their language specific knowledge and competencies.
Overall SCW Trust Agent delivers:
- Improved Security Controls: Customize policy configuration based on the sensitivity of project requirements
- Comprehensive Visibility: Actionable insights into the security posture of every commit across all of your code repositories
- Developer-Led Security at Scale: Deliver projects securely at speed - allowing application security teams to focus on the most sensitive security reviews
For more information on SCW Trust Agent, visit: www.scwtrustagent.com
About Secure Code Warrior
Secure Code Warrior is a secure coding platform that sets the standards that keep our digital world safe. We do this by providing the world’s leading agile learning platform that delivers the most effective secure coding solution for developers to learn, apply, and retain software security principles. More than 600 enterprises trust Secure Code Warrior to implement agile learning security programs and ensure the applications they release are free of vulnerabilities.
For more information about Secure Code Warrior, visit www.securecodewarrior.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723230392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom